IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Rhea-AI Summary

IN8bio (Nasdaq: INAB) promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective February 9, 2026. Dr. Rochlin has served as COO since December 2021 and held prior operations roles since August 2020.

She brings over 17 years of biotech experience and will continue to oversee operations, manufacturing, clinical programs and advancement of the company’s γδ T cell therapies and T cell engager pipeline, including INB-619 preclinical progress showing complete B cell depletion with limited cytokine release.

Positive

• Promotion creates combined President and COO leadership role
• Dr. Rochlin brings >17 years of biotech experience
• Continued oversight of operations, manufacturing, clinical programs
• INB-619 preclinical: complete B cell depletion with limited cytokine release
• Expanded GMP manufacturing support across Phase 1 and 2 programs

Negative

• None.

Key Figures

Industry experience: 17 years

1 metrics

Industry experience 17 years Dr. Kate Rochlin’s biotechnology company development experience

Market Reality Check

Price: $1.99 Vol: Volume 35,795 is at 0.42x...

low vol

$1.99 Last Close

Volume Volume 35,795 is at 0.42x the 20-day average of 84,512, indicating light trading ahead of/around this news. low

Technical Shares at $1.99 are trading below the 200-day MA $2.49 and remain 84.12% under the 52-week high.

Peers on Argus

INAB was up 4.74% while momentum data flagged only one peer (INTS, up 8.02%) and...

1 Up

INAB was up 4.74% while momentum data flagged only one peer (INTS, up 8.02%) and broader peers showed a mix of gains and losses, suggesting this move was stock-specific rather than a coordinated biotech sector swing.

Historical Context

5 past events · Latest: Feb 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	Conference participation	Positive	+1.5%	CEO scheduled to present at February investor and scientific conferences.
Jan 12	Clinical data update	Positive	-7.2%	Updated Phase 1/2 glioblastoma data showing improved mPFS and mOS vs SOC.
Dec 19	Private placement	Negative	-12.3%	Announcement of up to $40.2M private placement to fund INB-619 and other work.
Nov 06	Earnings and update	Neutral	+1.8%	Q3 2025 results and program updates including new INB-619 preclinical data.
Oct 29	Trial expansion	Positive	-4.8%	INB-100 Phase 1 trial expanded with new clinical site to accelerate enrollment.

Pattern Detected

Clinical and financing news have sometimes seen negative or mixed next-day reactions, while conferences and earnings have tended to produce modest positive moves.

Recent Company History

Over the last few months, IN8bio has highlighted multiple milestones, including updated Phase 1/2 glioblastoma data on Jan 12, 2026 and expansion of the INB-100 Phase 1 trial with a new site on Oct 29, 2025. Financing via a private placement of up to $40.2M was announced on Dec 19, 2025, and Q3 2025 results were reported on Nov 6, 2025. The current leadership promotion aligns with an ongoing build-out of clinical, manufacturing, and capital structures to support the γδ T cell pipeline.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-20

An effective Form S-3 dated Jan 20, 2026 registers up to 14,384,052 resale shares from a December 2025 private placement. The company is not selling shares and will receive no proceeds from these resales. The shelf is effective through Jan 20, 2029, and a related 424B3 prospectus was filed on Jan 30, 2026, indicating active usage of this resale registration.

Market Pulse Summary

This announcement highlights IN8bio’s decision to elevate its COO to President and COO as it advance...

Analysis

This announcement highlights IN8bio’s decision to elevate its COO to President and COO as it advances γδ T cell therapies and the INB-619 engager program. The move reinforces operational leadership across clinical, manufacturing, and regulatory functions. In context, the stock traded near $1.99 versus a $12.531 52-week high and below the $2.49 200-day MA. Investors may monitor execution on glioblastoma and autoimmune pipelines, the impact of registered resale shares, and progress toward future clinical milestones.

Key Terms

gamma-delta (γδ) t cell therapies, t cell engagers, preclinical, phase 1, +2 more

6 terms

gamma-delta (γδ) t cell therapies medical

"developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer"

A type of immunotherapy that uses a special subset of white blood cells called gamma-delta (γδ) T cells to find and kill infected or cancerous cells. Unlike most immune cells that need a specific ID badge to spot targets, these cells recognize stressed or abnormal cells more broadly, which could allow for off-the-shelf or more widely usable treatments. Investors care because successful γδ T‑cell therapies could alter drug pipelines, company valuations, and the competitive landscape for cancer and infectious disease treatments.

t cell engagers medical

"gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

preclinical medical

"as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

phase 1 medical

"teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

gmp manufacturing technical

"leading analytical, quality, regulatory and GMP manufacturing teams across multiple Phase"

GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately.

Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.

“Kate has been instrumental in translating IN8bio’s strategy into disciplined execution,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “Through her leadership and ability to align teams across operations, manufacturing, clinical, and research, she has played a central role in advancing our clinical programs, and T cell engager platform and delivering critical milestones on schedule. I am confident that her promotion to President will further strengthen the organization.”

Dr. Rochlin brings more than 17 years of experience across biotechnology company development, including scientific research, intellectual property, business development, clinical manufacturing and operations spanning corporate strategy, partnering, and team buildout. Prior to joining IN8bio, she was Chief Business Officer at Curadigm, a biotech developing precision-targeted drug delivery technologies, where she helped lead the company’s spin-out from Nanobiotix.

Since joining IN8bio, Dr. Rochlin has played a key role in advancing the company’s programs, including INB-619, a potential first-in-class, pan-γδ T cell engager for deep B cell depletion in autoimmune disease. IN8bio recently presented preclinical data showing that INB-619 achieved complete B cell depletion comparable to approved T cell engagers, with minimal adverse cytokine release and robust expansion of γδ T cells. These results validate the differentiation of IN8bio’s T cell engager platform and support continued regulatory engagement and advancement toward the clinic. Dr. Rochlin has also been instrumental in developing and expanding IN8bio’s clinical manufacturing program, leading analytical, quality, regulatory and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers.

“I’m honored to take on this expanded role and broader leadership responsibilities at such an important time for IN8bio,” said Dr. Rochlin. “With encouraging clinical data emerging from our γδ T cell therapy programs and novel gamma-delta T cell engager technology, we are well positioned to build on this momentum. I look forward to continuing to work closely with our team to execute on our corporate priorities and position IN8bio for long-term success.”

Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducted research at Sloan Kettering Institute, and earned a BA in Biology from the University of Pennsylvania.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell product candidates for unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The Company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact

Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/62811063-5de7-4e85-ab50-c1c32d410ea3

FAQ

Who is Kate Rochlin and what role did IN8bio (INAB) assign her on February 9, 2026?

Kate Rochlin was promoted to President and Chief Operating Officer effective February 9, 2026. According to the company, she previously served as COO since December 2021 and held operations and innovation leadership roles beginning in August 2020.

What experience does Dr. Kate Rochlin bring to her new IN8bio (INAB) President and COO role?

Dr. Rochlin brings more than 17 years of biotech experience across research, IP, business development and manufacturing. According to the company, her background includes roles in corporate strategy, partnering, clinical manufacturing, and prior service as Chief Business Officer at Curadigm.

How will Dr. Rochlin’s promotion affect IN8bio’s (INAB) clinical and manufacturing programs?

Her expanded role continues oversight of operations, GMP manufacturing, analytical and quality teams. According to the company, she will coordinate operations as IN8bio advances clinical and preclinical programs and prepares for the company’s next growth phase.

What recent preclinical result for IN8bio’s INB-619 did the company highlight with this leadership change?

IN8bio reported INB-619 achieved complete B cell depletion comparable to approved engagers, with minimal cytokine release. According to the company, these preclinical data support differentiation of its T cell engager platform and continued regulatory engagement.

Does Dr. Rochlin have prior leadership in manufacturing and clinical programs at IN8bio (INAB)?

Yes. She led expansion of IN8bio’s clinical manufacturing program and GMP teams across Phase 1 and 2 programs. According to the company, she directed analytical, quality, regulatory and manufacturing functions supporting glioblastoma and hematological cancer programs.